10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Sunday, April 3, 2011

Jenburkt Pharmaceuticals Ltd:-Buy/sell/hold,growth prospects and recomendation,news and results,target price and analysis,views and outlook

Scripscan:Jenburkt Pharmaceuticals Ltd

Story:.I seldom suggest pharma companies to you members as I hardly understand the business.Patent stuff,molecules,regular litigations are some daily issues which has kept me away from the sector.Jenburkt is an exceptional company and has impressed me a great deal be it the vision of the management or its well planned strategies.Jenburkt is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.Jenburkt pharma currently has 81 products and its variants in the domestic market while it exports around 25 products to 13 countries. It has 3 of its products currently under DPCO.As far as company`s network goes, in the domestic market its network consists of 26 Superstockists and Consignee Agents, about 1,000 Stockists and 45,000retailers.Company`s marketing team consists of 480 medical representatives and front line managers.Jenburkt's strategic decision to move up the value chain has started showing strong and positive results.The focus on long term therapies in acute and chronic ailments has begun contributing to the topline and bottom line strongly.A few brands of the company figures among the top 5 brands in their respective segments in the country and also internationally.The company has got a great dividend coverage ratio which helps under the present volatile environment.Last year it paid 3 bucks per share but with profits expected to be much higher this time a dividend of 4-5rs looks very much on.The promoters are busy accumulating shares from the market which speaks a lot about their confidence and conviction in the counter.Jenburkt is expected to post an EPS of 23 for fy12 which at present prices gives a PE of only 3.2.The company is also expected to be a debt free entity in near future.For a growing consistent company with a good management,decent productline,solid ROE's and ROCE,robust potential,hefty dividend yield of 6.5% and attractive valuation one coudnt just ask more.At 72rs its a great buy.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner